<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01656967</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-10-0604</org_study_id>
    <nct_id>NCT01656967</nct_id>
  </id_info>
  <brief_title>AMBU AScope2 Fiberoptic Intubation Versus Fastrach Intubating LMA</brief_title>
  <official_title>Flexible Optical Intubation Via the AMBU Aura-I Versus Blind Intubation Via the Fastrach Single Use Intubating LMA - A Prospective Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ambu A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare two types of supraglottic airways (SGA), the Ambu®
      Aura-I and the Intubating Laryngeal Mask Airway (ILMA), regarding time to intubate, ease of
      insertion, sealing properties, optical view upon fiberoptic examination regarding the Ambu
      Aura-I, ease and success rate of intubation, airway morbidity, and patient comfort in
      patients undergoing general anesthesia for elective surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include a total of 66 patients. Patients will be randomized into 2 groups
      through a computer generated randomization schedule. Patients in group A (N= 30) will be
      intubated using Ambu Aura-I and the Ambu aScope and patients in group B (N= 30) will be
      intubated using Intubating LMA. Patients will only be tested with one device.In the operating
      room, standard monitoring devices will be applied including a pulse oximeter, 3 lead (at
      least) ECG and blood pressure cuff; the latter could be invasive or non-invasive depending on
      the nature of the surgery. Baseline measures of BP, pulse, oxygen saturation, and CO2 will be
      made. The time will be noted before any sedation or anesthesia is administered. Vital signs
      will be recorded after induction of anesthesia, after insertion of SGA, and again after
      successful intubation.

      General anesthesia will be induced by bolus administration of propofol (1.5 to 2mg/kg) and
      fentanyl (1mcg/kg), and maintained with an inhalational agent. Rocuronium (0.6 mg/kg) will be
      administered to provide muscle relaxation and a mixture of sevoflurane or isoflurane and
      nitrous oxide will be utilized for maintenance of anesthesia once the ability to mask
      ventilate is confirmed. The lungs will be mechanically ventilated with a semi-closed circle
      system to maintain an end-tidal CO2 near 35 mmHg. Patients' lungs will be ventilated via
      anesthesia mask 100% oxygen until the patient is completely relaxed.

      The size of the SGA device used will be based on manufacturer's recommendations and clinical
      evaluation of the anesthesiologist. The SGA device will be placed using standard technique
      and jaw lift will always be performed to aid in placement. The user will record ease of
      insertion on a scale (1-5) and number of insertions required will also be recorded. A new
      attempt is considered to begin if the tip of the cuff is withdrawn to the level of the lips.
      Accurate ventilation is achieved when the CO2 signal is rectangular and the mask is airtight
      at a respiratory pressure of up to 20 cm H2O. Time will be recorded from when the tip of the
      device cuff is at the mouth opening and stopped when first CO2 waveform is recorded.

      Once ventilation is achieved, the patients in group A will be intubated through the shaft of
      Aura-I via the the Ambu aScope. If the epiglottis is down folded and obscuring optical view,
      jaw lift can be performed by an assistant to improve visualization of the cords. The aScope
      will be advanced until the carina is visualized and then the ETT is railroaded via the aScope
      into position (5cm above carina or cuff of ETT just below vocal cords). Once the ETT is
      successfully inserted, the cuff of the Aura-I will be deflated and the patient is ventilated
      via the ETT. If it is not possible to intubate, the ETT should be rotated 90°
      counterclockwise and jaw lift should be performed to help with intubation. If unsuccessful
      after two attempts, the anesthesiologist will proceed to intubate in standard fashion. The
      patients in group B will be intubated by ETT via the Intubating LMA as is standard procedure.

      Once the procedure has finished and the patient is adequately reversed as determined by nerve
      stimulation, the cuff will be reinflated and the ETT will be removed. Ventilation will resume
      via the SGA. Once the ETT is withdrawn, the cuff will be adjusted to 60cm H2O using a cuff
      pressure manometer. The oropharyngeal leak pressure(OLP) is determined with a 60 cm H2O
      intracuff pressure by closing the expiratory spill valve and then closing the expiratory
      valve of the circle system at a fixed gas flow of 3 L/min, without any respiration. The
      airway pressure at which equilibrium is reached and air leaks from the mouth or into the
      stomach, as sign of leak of the laryngeal mask is noted. Esophageal leak is determined by
      stethoscopy of the epigastrium and oropharyngeal leak is dectected listening for air leak
      over the mouth.

      The peak airway pressure is not allowed to exceed 40 cmH2O. After OLP measurement and once
      the patient is adequately breathing on their own, the SGA can be removed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Intubation Time</measure>
    <time_frame>Duration of Intubation, including supraglottic airway (SGA) insertion and endotracheal tube (ETT) insertion</time_frame>
    <description>Total Intubation Time includes time for SGA insertion and for ETT insertion. The total time to intubation was measured from the beginning of SGA insertion to successful endotracheal tube intubation verified by detection of CO2 on the capnogram.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time for Supraglottic Airway (SGA) Insertion</measure>
    <time_frame>At SGA insertion</time_frame>
    <description>Time for SGA insertion was measured from when the tip of the cuff was at the mouth to detection of CO2 on the capnogram.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for Endotracheal Tube (ETT) Insertion</measure>
    <time_frame>At ETT insertion</time_frame>
    <description>After the SGA is inserted, time for intubation will be recorded. Time for ETT insertion was measured, for arm 1, from when the AMBU aScope is at the connector level of the Aura-I or, for arm 2, from when the ETT is at the connector level of the Intubating LMA to first detection of CO2 on the capnogram. The AScope 2 disposable fiberoptic camera will be used to assist with intubation for Group 1 patients. Group 2 patients will be intubated using the LMA-Fastrach EndoTracheal Tube.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Whom SGA Insertion Was Successful on the First Attempt</measure>
    <time_frame>At SGA insertion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Whom ETT Insertion Was Successful on the First Attempt</measure>
    <time_frame>At ETT insertion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Overall Success for SGA Placement</measure>
    <time_frame>At SGA insertion</time_frame>
    <description>Ease of SGA insertion is subjectively assessed by the operator on a scale from 1 to 5 (1 = extremely easy, 5 = extremely difficult).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Overall Intubation Success</measure>
    <time_frame>At ETT insertion</time_frame>
    <description>Ease of ETT insertion is subjectively assessed by the operator on a scale from 1 to 5 (1 = extremely easy, 5 = extremely difficult).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-Operative Discomfort Upon Entering the Post-Anesthesia Care Unit (PACU)</measure>
    <time_frame>Within 30 minutes of completion of surgery</time_frame>
    <description>The patient will be assessed for Post-Operative Hoarseness, Sore Mouth, Sore Neck, Sore Jaw, Dysphonia, Dysphagia, and Altered Tongue Sensation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-Operative Discomfort Upon Leaving the Post-Anesthesia Care Unit (PACU)</measure>
    <time_frame>Approximately 1-2 hours after entering the PACU</time_frame>
    <description>The patient will be assessed for Post-Operative Hoarseness, Sore Mouth, Sore Neck, Sore Jaw, Dysphonia, Dysphagia, and Altered Tongue Sensation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Orolaryngeal Pressure</measure>
    <time_frame>Following SGA Insertion</time_frame>
    <description>The oropharyngeal leak pressure (OLP) was determined by closing the expiratory valve of the circle system at a fixed gas flow of 3 L/min and noting the airway pressure at which equilibrium was reached (not permitted to exceed 40 cm H2O).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Supraglottic Airway</condition>
  <arm_group>
    <arm_group_label>AMBU Aura-I/aScope 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First, the AMBU Aura-I LMA will be inserted. Then, the patient will be intubated with assistance of the AMBU aScope 2 disposable fiberoptic system.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LMA Fastrach</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The LMA Fastrach Single Use Laryngeal Mask Airway will be placed, followed by blind intubation using the LMA Fastrach EndoTracheal Tube.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AMBU Aura-I/aScope 2</intervention_name>
    <description>Once ventilation is achieved, the patients in group A will be intubated through the shaft of Aura-I via the the Ambu aScope.</description>
    <arm_group_label>AMBU Aura-I/aScope 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LMA Fastrach Single Use</intervention_name>
    <description>The patients in group B will be intubated by ETT via the Intubating LMA as is standard procedure.</description>
    <arm_group_label>LMA Fastrach</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult surgical Candidates Aged 18-80 years

          -  ASA I-III

          -  Mallampati Score of I or II

          -  BMI ≤ 35 kg/m2

          -  Presenting for elective surgery

          -  Require General Endotracheal Anesthesia.

        Exclusion Criteria:

          -  Previously known difficult airway,

          -  Emergency status

          -  Require prone positioning

          -  Interincisor distance &lt; 2.5cm

          -  Thyromental distance &lt; 5cm

          -  Clinically suspected difficult airway

          -  Contraindications to LMA Insertion, such as Reflux disease

          -  Patients who do not require endotracheal intubation

          -  Indications for Rapid Sequence Induction (RSI)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carin A Hagberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Medical School at Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Hermann Hospital - Texas Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2012</study_first_submitted>
  <study_first_submitted_qc>August 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2012</study_first_posted>
  <results_first_submitted>March 22, 2016</results_first_submitted>
  <results_first_submitted_qc>March 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 22, 2016</results_first_posted>
  <last_update_submitted>November 29, 2016</last_update_submitted>
  <last_update_submitted_qc>November 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Carin A. Hagberg</investigator_full_name>
    <investigator_title>Professor and Chair, Department of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Laryngeal Mask Airway</keyword>
  <keyword>LMA</keyword>
  <keyword>Intubation</keyword>
  <keyword>AMBU</keyword>
  <keyword>AScope</keyword>
  <keyword>Aura-I</keyword>
  <keyword>Fastrach</keyword>
  <keyword>Fiberoptic</keyword>
  <keyword>Disposable Fiberoptic</keyword>
  <keyword>Blind Intubation</keyword>
  <keyword>Fiberoptic Intubation</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AMBU Aura-I/aScope 2</title>
          <description>First, the AMBU Aura-I LMA will be inserted. Then, then patient will be intubated with assistance of the AMBU aScope 2 disposable fiberoptic system.
AMBU Aura-I LMA and aScope 2 Disposable Fiberoptic Camera</description>
        </group>
        <group group_id="P2">
          <title>LMA Fastrach</title>
          <description>The LMA Fastrach Single Use Laryngeal Mask Airway (The Laryngeal Mask Airway Company, California) will be placed, followed by blind intubation using the LMA Fastrach EndoTracheal Tube.
LMA Fastrach Single Use</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>SGA Placement</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>ETT Insertion</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>faulty monitor</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>unsuccessful ETT insertion</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled patients, except for one in the Ambu group who was withdrawn due to a faulty monitor</population>
      <group_list>
        <group group_id="B1">
          <title>AMBU Aura-I/aScope 2</title>
          <description>First, the AMBU Aura-I LMA will be inserted. Then, then patient will be intubated with assistance of the AMBU aScope 2 disposable fiberoptic system.
AMBU Aura-I LMA and aScope 2 Disposable Fiberoptic Camera</description>
        </group>
        <group group_id="B2">
          <title>LMA Fastrach</title>
          <description>The LMA Fastrach Single Use Laryngeal Mask Airway (The Laryngeal Mask Airway Company, California) will be placed, followed by blind intubation using the LMA Fastrach EndoTracheal Tube.
LMA Fastrach Single Use</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.8" spread="13.7"/>
                    <measurement group_id="B2" value="44.4" spread="13.7"/>
                    <measurement group_id="B3" value="42.1" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Intubation Time</title>
        <description>Total Intubation Time includes time for SGA insertion and for ETT insertion. The total time to intubation was measured from the beginning of SGA insertion to successful endotracheal tube intubation verified by detection of CO2 on the capnogram.</description>
        <time_frame>Duration of Intubation, including supraglottic airway (SGA) insertion and endotracheal tube (ETT) insertion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AMBU Aura-I/aScope 2</title>
            <description>First, the AMBU Aura-I LMA will be inserted. Then, then patient will be intubated with assistance of the AMBU aScope 2 disposable fiberoptic system.
AMBU Aura-I LMA and aScope 2 Disposable Fiberoptic Camera</description>
          </group>
          <group group_id="O2">
            <title>LMA Fastrach</title>
            <description>The LMA Fastrach Single Use Laryngeal Mask Airway (The Laryngeal Mask Airway Company, California) will be placed, followed by blind intubation using the LMA Fastrach EndoTracheal Tube.
LMA Fastrach Single Use</description>
          </group>
        </group_list>
        <measure>
          <title>Total Intubation Time</title>
          <description>Total Intubation Time includes time for SGA insertion and for ETT insertion. The total time to intubation was measured from the beginning of SGA insertion to successful endotracheal tube intubation verified by detection of CO2 on the capnogram.</description>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.6" lower_limit="67.8" upper_limit="117.5"/>
                    <measurement group_id="O2" value="52.1" lower_limit="46.4" upper_limit="69.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time for Supraglottic Airway (SGA) Insertion</title>
        <description>Time for SGA insertion was measured from when the tip of the cuff was at the mouth to detection of CO2 on the capnogram.</description>
        <time_frame>At SGA insertion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AMBU Aura-I/aScope 2</title>
            <description>First, the AMBU Aura-I LMA will be inserted. Then, then patient will be intubated with assistance of the AMBU aScope 2 disposable fiberoptic system.
AMBU Aura-I LMA and aScope 2 Disposable Fiberoptic Camera</description>
          </group>
          <group group_id="O2">
            <title>LMA Fastrach</title>
            <description>The LMA Fastrach Single Use Laryngeal Mask Airway (The Laryngeal Mask Airway Company, California) will be placed, followed by blind intubation using the LMA Fastrach EndoTracheal Tube.
LMA Fastrach Single Use</description>
          </group>
        </group_list>
        <measure>
          <title>Time for Supraglottic Airway (SGA) Insertion</title>
          <description>Time for SGA insertion was measured from when the tip of the cuff was at the mouth to detection of CO2 on the capnogram.</description>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" lower_limit="20.9" upper_limit="37.9"/>
                    <measurement group_id="O2" value="30.3" lower_limit="23.0" upper_limit="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time for Endotracheal Tube (ETT) Insertion</title>
        <description>After the SGA is inserted, time for intubation will be recorded. Time for ETT insertion was measured, for arm 1, from when the AMBU aScope is at the connector level of the Aura-I or, for arm 2, from when the ETT is at the connector level of the Intubating LMA to first detection of CO2 on the capnogram. The AScope 2 disposable fiberoptic camera will be used to assist with intubation for Group 1 patients. Group 2 patients will be intubated using the LMA-Fastrach EndoTracheal Tube.</description>
        <time_frame>At ETT insertion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AMBU Aura-I/aScope 2</title>
            <description>First, the AMBU Aura-I LMA will be inserted. Then, then patient will be intubated with assistance of the AMBU aScope 2 disposable fiberoptic system.
AMBU Aura-I LMA and aScope 2 Disposable Fiberoptic Camera</description>
          </group>
          <group group_id="O2">
            <title>LMA Fastrach</title>
            <description>The LMA Fastrach Single Use Laryngeal Mask Airway (The Laryngeal Mask Airway Company, California) will be placed, followed by blind intubation using the LMA Fastrach EndoTracheal Tube.
LMA Fastrach Single Use</description>
          </group>
        </group_list>
        <measure>
          <title>Time for Endotracheal Tube (ETT) Insertion</title>
          <description>After the SGA is inserted, time for intubation will be recorded. Time for ETT insertion was measured, for arm 1, from when the AMBU aScope is at the connector level of the Aura-I or, for arm 2, from when the ETT is at the connector level of the Intubating LMA to first detection of CO2 on the capnogram. The AScope 2 disposable fiberoptic camera will be used to assist with intubation for Group 1 patients. Group 2 patients will be intubated using the LMA-Fastrach EndoTracheal Tube.</description>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.9" lower_limit="41.0" upper_limit="84.0"/>
                    <measurement group_id="O2" value="23.1" lower_limit="20.6" upper_limit="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Whom SGA Insertion Was Successful on the First Attempt</title>
        <time_frame>At SGA insertion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AMBU Aura-I/aScope 2</title>
            <description>First, the AMBU Aura-I LMA will be inserted. Then, then patient will be intubated with assistance of the AMBU aScope 2 disposable fiberoptic system.
AMBU Aura-I LMA and aScope 2 Disposable Fiberoptic Camera</description>
          </group>
          <group group_id="O2">
            <title>LMA Fastrach</title>
            <description>The LMA Fastrach Single Use Laryngeal Mask Airway (The Laryngeal Mask Airway Company, California) will be placed, followed by blind intubation using the LMA Fastrach EndoTracheal Tube.
LMA Fastrach Single Use</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Whom SGA Insertion Was Successful on the First Attempt</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Whom ETT Insertion Was Successful on the First Attempt</title>
        <time_frame>At ETT insertion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AMBU Aura-I/aScope 2</title>
            <description>First, the AMBU Aura-I LMA will be inserted. Then, then patient will be intubated with assistance of the AMBU aScope 2 disposable fiberoptic system.
AMBU Aura-I LMA and aScope 2 Disposable Fiberoptic Camera</description>
          </group>
          <group group_id="O2">
            <title>LMA Fastrach</title>
            <description>The LMA Fastrach Single Use Laryngeal Mask Airway (The Laryngeal Mask Airway Company, California) will be placed, followed by blind intubation using the LMA Fastrach EndoTracheal Tube.
LMA Fastrach Single Use</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Whom ETT Insertion Was Successful on the First Attempt</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Overall Success for SGA Placement</title>
        <description>Ease of SGA insertion is subjectively assessed by the operator on a scale from 1 to 5 (1 = extremely easy, 5 = extremely difficult).</description>
        <time_frame>At SGA insertion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AMBU Aura-I/aScope 2</title>
            <description>First, the AMBU Aura-I LMA will be inserted. Then, then patient will be intubated with assistance of the AMBU aScope 2 disposable fiberoptic system.
AMBU Aura-I LMA and aScope 2 Disposable Fiberoptic Camera
first-attempt success rate for SGA placement for the Aura-i group (30/33, 90.9%)</description>
          </group>
          <group group_id="O2">
            <title>LMA Fastrach</title>
            <description>The LMA Fastrach Single Use Laryngeal Mask Airway (The Laryngeal Mask Airway Company, California) will be placed, followed by blind intubation using the LMA Fastrach EndoTracheal Tube.
LMA Fastrach Single Use
first-attempt success rate for SGA placement for the ILMA group (30/33, 90.9%, P = 1.0)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Overall Success for SGA Placement</title>
          <description>Ease of SGA insertion is subjectively assessed by the operator on a scale from 1 to 5 (1 = extremely easy, 5 = extremely difficult).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Overall Intubation Success</title>
        <description>Ease of ETT insertion is subjectively assessed by the operator on a scale from 1 to 5 (1 = extremely easy, 5 = extremely difficult).</description>
        <time_frame>At ETT insertion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AMBU Aura-I/aScope 2</title>
            <description>First, the AMBU Aura-I LMA will be inserted. Then, then patient will be intubated with assistance of the AMBU aScope 2 disposable fiberoptic system.
AMBU Aura-I LMA and aScope 2 Disposable Fiberoptic Camera
first-attempt success rate for SGA placement for the Aura-i group (30/33, 90.9%)</description>
          </group>
          <group group_id="O2">
            <title>LMA Fastrach</title>
            <description>The LMA Fastrach Single Use Laryngeal Mask Airway (The Laryngeal Mask Airway Company, California) will be placed, followed by blind intubation using the LMA Fastrach EndoTracheal Tube.
LMA Fastrach Single Use
first-attempt success rate for SGA placement for the ILMA group (30/33, 90.9%, P = 1.0)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Overall Intubation Success</title>
          <description>Ease of ETT insertion is subjectively assessed by the operator on a scale from 1 to 5 (1 = extremely easy, 5 = extremely difficult).</description>
          <units>participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-Operative Discomfort Upon Entering the Post-Anesthesia Care Unit (PACU)</title>
        <description>The patient will be assessed for Post-Operative Hoarseness, Sore Mouth, Sore Neck, Sore Jaw, Dysphonia, Dysphagia, and Altered Tongue Sensation.</description>
        <time_frame>Within 30 minutes of completion of surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-Operative Discomfort Upon Leaving the Post-Anesthesia Care Unit (PACU)</title>
        <description>The patient will be assessed for Post-Operative Hoarseness, Sore Mouth, Sore Neck, Sore Jaw, Dysphonia, Dysphagia, and Altered Tongue Sensation.</description>
        <time_frame>Approximately 1-2 hours after entering the PACU</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Orolaryngeal Pressure</title>
        <description>The oropharyngeal leak pressure (OLP) was determined by closing the expiratory valve of the circle system at a fixed gas flow of 3 L/min and noting the airway pressure at which equilibrium was reached (not permitted to exceed 40 cm H2O).</description>
        <time_frame>Following SGA Insertion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AMBU Aura-I/aScope 2</title>
            <description>First, the AMBU Aura-I LMA will be inserted. Then, then patient will be intubated with assistance of the AMBU aScope 2 disposable fiberoptic system.
AMBU Aura-I LMA and aScope 2 Disposable Fiberoptic Camera</description>
          </group>
          <group group_id="O2">
            <title>LMA Fastrach</title>
            <description>The LMA Fastrach Single Use Laryngeal Mask Airway (The Laryngeal Mask Airway Company, California) will be placed, followed by blind intubation using the LMA Fastrach EndoTracheal Tube.
LMA Fastrach Single Use</description>
          </group>
        </group_list>
        <measure>
          <title>Orolaryngeal Pressure</title>
          <description>The oropharyngeal leak pressure (OLP) was determined by closing the expiratory valve of the circle system at a fixed gas flow of 3 L/min and noting the airway pressure at which equilibrium was reached (not permitted to exceed 40 cm H2O).</description>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0" lower_limit="24.5" upper_limit="30.0"/>
                    <measurement group_id="O2" value="26.0" lower_limit="24.0" upper_limit="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Event data include measures of post-operative discomfort upon entering the Post-Anesthesia Care Unit (PACU). Patients entered the PACU within 30 minutes of completion of surgery. Data collected for 6 months duration.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AMBU Aura-I/aScope 2</title>
          <description>First, the AMBU Aura-I LMA will be inserted. Then, then patient will be intubated with assistance of the AMBU aScope 2 disposable fiberoptic system.
AMBU Aura-I LMA and aScope 2 Disposable Fiberoptic Camera</description>
        </group>
        <group group_id="E2">
          <title>LMA Fastrach</title>
          <description>The LMA Fastrach Single Use Laryngeal Mask Airway (The Laryngeal Mask Airway Company, California) will be placed, followed by blind intubation using the LMA Fastrach EndoTracheal Tube.
LMA Fastrach Single Use</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" events="13" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="16" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sore mouth</sub_title>
                <counts group_id="E1" events="29" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" events="31" subjects_affected="8" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sore neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sore Jaw</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="7" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" events="22" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Altered tongue sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Experience of the residents, some only had 6 months experience When using AScope, there were secretions and no suctioning capability Sample size ILMA is a straightforward attempt; whereas, AScope needs to maneuver and go all the way to carina</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Carin A. Hagberg</name_or_title>
      <organization>The University of Texas Health Science Center at Houston</organization>
      <phone>(713) 500-6240</phone>
      <email>Carin.A.Hagberg@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

